Primary Care Pulse: Recorded Live on January 26, 2021

Thank you to all who joined us live Primary Care Pulse on January 26, 2021. If you were not able to join us live, the sessions have been recorded and are available below.

Upcoming Virtual Programs
Join your clinician colleagues and expert faculty as they present the latest clinical insights and guidelines during a variety of upcoming virtual education opportunities, including Primary Care Pulse and PrimaryCareNOW. View our upcoming virtual conference schedule.

Virtual Programs


  CME/CE Accredited Session

Non-CME/CE Session
Sponsored by Industry

Click For Session Details
Session Times Listed in ET

12–12:30pm ET    CME/CE Accredited Session

Infectious Diseases

COVID-19 Web Series Part 24: Vaccine Update and Genetic Variants  

Ty J. Gluckman, MD, FACC, FAHA | Charles Vega, MD, FAAFP


Join us for the first COVID-19 Pulse session of 2021! In the twenty-fourth episode of Pri-Med’s web series on COVID-19, faculty will walk through the 
Advisory Committee on Immunization Practices (ACIP) guidelines for COVID-19 vaccine prioritization as well as the newest data on these vaccines. This session will discuss the emerging SARS-CoV-2 variants and their potential implications. Faculty will conclude with a Q&A session to answer your most pressing COVID-19 questions.

Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 1/26/2021 and they are subject to change as new information is published.


Ty J. Gluckman, MD, FACC, FAHA

Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, OR

Charles Vega, MD, FAAFP

Health Sciences Clinical Professor, UC Irvine Department of Family Medicine, Assistant Dean for Culture and Community Education, Executive Director, UC Irvine Program in Medical Education for the Latino Community, UC Irvine School of Medicine, Irvine, CA

12:40–1:25pm ET    Non-CME Industry Theater



  • Understand the disease burden and pathophysiology for acute ischemic stroke (AIS), and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk transient ischemic attack (TIA).
  • Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y12 inhibitor use in this patient population
  • Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial

Ted Okerson, MD, FACP, FACE

Sponsored by AstraZeneca